UK markets closed

Adocia SA (0QAI.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
8.72+0.36 (+4.31%)
At close: 05:53PM GMT
Full screen
Previous close8.36
Open8.94
Bid0.00 x 0
Ask0.00 x 0
Day's range8.72 - 8.94
52-week range2.80 - 16.16
Volume877
Avg. volume3,256
Market cap608,536
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance

    LYON, France, March 21, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that it has obtained two financing operations, with the issuance of ordinary shares to the benefit of members of its management team, including the founding Soula family, and Vester Finance under the form of a capital increase wi

  • Business Wire

    Number of Shares and Voting Rights of Adocia as of February 29th, 2024

    LYON, France, March 15, 2024--Regulatory News: Pursuant to the provisions of article L. 233-8 II of the French « Code de Commerce » and article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC) a clinical stage biopharmaceutical company focused on treatment of diabetes, obesity and metabolic diseases with innovat

  • Business Wire

    ADOCIA Announces Its Participation at Key Events

    LYON, France, March 06, 2024--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that its management team are scheduled to participate in the following upcoming conferences: